Marker Therapeutics, Inc.
MRKR
Price:
$3.06
Market Cap:
$27.30M
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and...[Read more]
Industry
Biotechnology
IPO Date
2002-07-16
Stock Exchange
NASDAQ
Ticker
MRKR
The ROE as of September 2024 (TTM) for Marker Therapeutics, Inc. (MRKR) is -78.91%
According to Marker Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -78.91%. This represents a change of 293.34% compared to the average of -20.06% of the last 4 quarters.
Marker Therapeutics, Inc. (MRKR) Historical ROE (quarterly & annually)
How has MRKR ROE performed in the past?
The mean historical ROE of Marker Therapeutics, Inc. over the last ten years is 206.82%. The current -78.91% ROE has changed -138.15% with respect to the historical average. Over the past ten years (40 quarters), MRKR's ROE was at its highest in in the September 2014 quarter at 238.93%. The ROE was at its lowest in in the September 2018 quarter at -635.57%.
Average
206.82%
Median
-99.76%
Minimum
-300.21%
Maximum
3.02%
Marker Therapeutics, Inc. (MRKR) ROE by Quarter and Year
Discovering the peaks and valleys of Marker Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.68%
Maximum Annual ROE = 3.02%
Minimum Annual Increase = -124.89%
Minimum Annual ROE = -300.21%
| Year | ROE | Change |
|---|---|---|
| 2023 | -120.75% | -20.88% |
| 2022 | -152.62% | 60.32% |
| 2021 | -95.20% | -8.75% |
| 2020 | -104.32% | 126.26% |
| 2019 | -46.11% | -81.51% |
| 2018 | -249.34% | -16.95% |
| 2017 | -300.21% | 656.17% |
| 2016 | -39.70% | -124.89% |
| 2015 | 159.48% | -94.71% |
| 2014 | 3.02% | 4.68% |
Marker Therapeutics, Inc. (MRKR) Average ROE
How has MRKR ROE performed in the past?
The current ROE of Marker Therapeutics, Inc. (MRKR) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-122.86%
5-year avg
-103.80%
10-year avg
206.82%
Marker Therapeutics, Inc. (MRKR) ROE vs. Peers
How is MRKR’s ROE compared to its peers?
Marker Therapeutics, Inc.’s ROE is greater than Lumos Pharma, Inc. (-157.99%), greater than Exicure, Inc. (-288.03%), greater than Protagenic Therapeutics, Inc. (-238.37%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Miromatrix Medical Inc. (-119.21%), less than ZIVO Bioscience, Inc. (673.84%), greater than Bionomics Limited (-150.24%), less than Agenus Inc. (122.08%), greater than Icosavax, Inc. (-41.24%), less than Galera Therapeutics, Inc. (21.95%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than RenovoRx, Inc. (-403.38%), greater than Tempest Therapeutics, Inc. (-201.10%), greater than Ikena Oncology, Inc. (-42.81%), less than Catalyst Biosciences, Inc. (1.20%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.31%), greater than Alector, Inc. (-102.63%), greater than Aadi Bioscience, Inc. (-66.67%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Aerovate Therapeutics, Inc. (-83.65%),
| Company | ROE | Market cap |
|---|---|---|
| -157.99% | $30.64M | |
| -288.03% | $3.22M | |
| -238.37% | $3.29M | |
| -21.96% | $77.79M | |
| -122.97% | $46.68M | |
| -119.21% | $92.95M | |
| 673.84% | $45.27M | |
| -150.24% | $7.29M | |
| 122.08% | $105.06M | |
| -41.24% | $769.04M | |
| 21.95% | $4.07M | |
| -28.01% | $1.61B | |
| -403.38% | $24.23M | |
| -201.10% | $31.38M | |
| -42.81% | $81.08M | |
| 1.20% | $19.42M | |
| -47.31% | $251.18M | |
| -102.63% | $466.32M | |
| -66.67% | $45.29M | |
| -44.73% | $1.97B | |
| -83.65% | $54.27M |
Build a custom stock screener for Marker Therapeutics, Inc. (MRKR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Marker Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Marker Therapeutics, Inc. (MRKR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Marker Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Marker Therapeutics, Inc.'s ROE?
How is the ROE calculated for Marker Therapeutics, Inc. (MRKR)?
What is the highest ROE for Marker Therapeutics, Inc. (MRKR)?
What is the 3-year average ROE for Marker Therapeutics, Inc. (MRKR)?
What is the 5-year average ROE for Marker Therapeutics, Inc. (MRKR)?
How does the current ROE for Marker Therapeutics, Inc. (MRKR) compare to its historical average?